Breakthrough Solution for Respiratory Infections

About us

Signia Therapeutics is an innovative French start-up from the VirPath laboratory of the University Claude Bernard (Lyon).

SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several market-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.

A major public health issue

Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens constitute a major public health issue and represent a large socio-economic impact.

Up to now, very few efficient vaccines or antiviral candidate treatments have been reported in the medical literature to widely fight against these respiratory pathogens, except for those available against influenza viruses. In an effort to treat these various ARTIs, consumers spend more than $2-3 billion each year, yet new efficient antiviral strategies, less prone to the emergence of resistance, are necessary.